← All trials
NCT05922683
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2023
- Primary completion
- Jun 30, 2024
- Completion date
- Dec 31, 2024
- First posted
- Jun 28, 2023
- Last posted
- Jun 28, 2023
- Enrollment
- 76
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Aga Khan UniversityLead sponsor
- Institut PasteurCollaborator
- University of ZambiaCollaborator
- Aga Khan UniversityOverall official - principal investigator
- Aga Khan UniversityReponsible party - principal investigator
- International Center for Diarrheal Disease ResearchCollaborator
- Bill and Melinda Gates FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.